Skip to main content

New spin-off Abscint tackles diseases with molecular imaging

  • February 10, 2021

A new VUB spin-off named ABSCINT NV was established, based on technology developed by the joint research efforts of the teams of Prof. Dr. Tony Lahoutte and Prof. Dr.  Jo Van Ginderachter at VUB and VIB. ABSCINT is a clinical stage molecular imaging company that develops diagnostics based on single domain antibodies. Single domain antibodies are unique molecules that were originally discovered at VUB and have been the basis of a number of successful biotech companies.

ABSCINT will focus on the development of radiolabeled single domain antibodies for whole body molecular imaging applications. Molecular imaging is used for the diagnosis of disease, for treatment selection, and monitoring treatment response based on specific molecular markers that can be visualised over the entire body by a short scan. The company has two clinical stage products: one in oncology and one in cardiovascular disease.

Read more